PerspectiveCANCER

Reprogramming to resist

See allHide authors and affiliations

Science  06 Jan 2017:
Vol. 355, Issue 6320, pp. 29-30
DOI: 10.1126/science.aam5355

You are currently viewing the summary.

View Full Text

Summary

One means by which cancer cells evade therapies involves their ability to reprogram to a cell type that no longer depends on the cellular pathway being targeted by the treatments. Hormone deprivation therapies that suppress androgen receptor (AR) signaling are the mainstay of treatment for metastatic prostate cancer. However, prostate cancers can become resistant to this approach by losing dependence on androgen hormones. On pages 84 and 78 of this issue, Mu et al. (1) and Ku et al. (2), respectively, contribute to our mechanistic understanding of this remarkable plasticity in cell identity, which allows cancers to thrive.